<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737616</url>
  </required_header>
  <id_info>
    <org_study_id>HS# 2019-5446</org_study_id>
    <nct_id>NCT04737616</nct_id>
  </id_info>
  <brief_title>Continuous Monitoring and Management of Vaginal Health Via Multifunctional OCT/OCTA/OCE Endoscopy</brief_title>
  <official_title>Continuous Monitoring and Management of Vaginal Health Via Multifunctional 1.7um Optical Coherence Tomography/Angiography Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We have recently developed and optimized a vaginal Optical Coherence tomography/angiography&#xD;
      endoscopy imaging system. This technology is able to obtain a comprehensive image of the&#xD;
      vaginal epithelium, blood vessels, and lamina propria. The primary focus of this study is&#xD;
      establishing the Optical Coherence Tomography system's capability of capturing vaginal&#xD;
      changes that occur before and after menopause, as well as before and after treatment with&#xD;
      fractional-CO2 laser therapy.&#xD;
&#xD;
      There are two aims of this study.&#xD;
&#xD;
      Aim 1:&#xD;
&#xD;
      1. To determine the feasibility and sensitivity of the integrated optical coherence endoscope&#xD;
      to assess vaginal tissue integrity in pre, peri and postmenopausal women.&#xD;
&#xD;
      Aim 2:&#xD;
&#xD;
      To optically visualize the effects of fractional-CO2 laser treatment on vaginal tissue over&#xD;
      the course of C02 vaginal laser therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaginal Optical Coherence tomography/angiography endoscopy imaging system. This&#xD;
      technology is able to obtain a comprehensive image of the vaginal epithelium, blood vessels,&#xD;
      and lamina propria. The primary focus of this study is establishing the Optical Coherence&#xD;
      Tomography system's capability of capturing vaginal changes that occur before and after&#xD;
      menopause, as well as before and after treatment with fractional-CO2 laser therapy.&#xD;
&#xD;
      There are two aims of this study.&#xD;
&#xD;
      Aim 1: To determine the feasibility and sensitivity of the integrated optical coherence&#xD;
      endoscope to assess vaginal tissue integrity in pre, peri and postmenopausal women&#xD;
&#xD;
      We will enroll up to 90 women (age: 18 and older) who will be classified as pre-menopausal,&#xD;
      peri- menopausal, or post-menopausal. There will be 30 women in each group. All enrolled&#xD;
      subjects will first complete informed consents.&#xD;
&#xD;
      They will then fill out a questionnaire (the vulvovaginal symptom questionnaire) about their&#xD;
      vaginal health. This will be followed by a pelvic exam to determine the vaginal health&#xD;
      (vaginal health index) and to obtain a vaginal swab for assessment of the vaginal microbiome&#xD;
      .&#xD;
&#xD;
      This will be followed by OCT scan of the vaginal tissue. There will be only one visit.&#xD;
&#xD;
      Aim 2: To optically visualize the effects of fractional-CO2 laser treatment on vaginal tissue&#xD;
      over the course of C02 vaginal laser therapy.&#xD;
&#xD;
      Up to thirty Post-menopausal subjects with GSM who desire fractional-CO2 laser therapy, will&#xD;
      be recruited.&#xD;
&#xD;
      Each visit will include: completion of a questionnaire (the vulvovaginal symptom&#xD;
      questionnaire) about their vaginal health; followed by a pelvic exam to determine the vaginal&#xD;
      health (vaginal health index) and to obtain a vaginal swab for assessment of the vaginal&#xD;
      microbiome and an OCT scan of the vaginal tissue before the CO2 vaginal laser treatment.&#xD;
&#xD;
      This group will have a total of three visits with CO2 laser treatments. There will be a&#xD;
      fourth visit which will include all the above study procedures except the CO2 laser&#xD;
      treatment.&#xD;
&#xD;
      Subjects who complete 3 laser treatments will be offered participation in long term follow up&#xD;
      with repeat OCT imaging every 3 months at 3, 6, 9 and 12 months after the final laser&#xD;
      treatment to study the long- term effects of the laser treatment on the vaginal tissue.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal epithelial thickness (VET)</measure>
    <time_frame>2 years</time_frame>
    <description>Vaginal epithelium thickness measured with the OCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood vessel density</measure>
    <time_frame>2 years</time_frame>
    <description>The blood vessel density will be measured by OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal Health Index (VHI)</measure>
    <time_frame>2 years</time_frame>
    <description>VHI to be measured on exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactobacillus abundance</measure>
    <time_frame>2 years</time_frame>
    <description>Lactobacillus abundance by RNA sequencing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Genitourinary Syndrome of Menopause</condition>
  <arm_group>
    <arm_group_label>CO2 Laser +OCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal women with genitourinary syndrome of menopause who will receive CO2 vaginal laser treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCT only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premenopausal, peri-menopausal and postmenopausal women who will only get one time OCT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 laser</intervention_name>
    <description>Fractional CO2 vaginal laser for genitourinary syndrome of menopause</description>
    <arm_group_label>CO2 Laser +OCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>Optical coherence tomography endoscope</description>
    <arm_group_label>CO2 Laser +OCT</arm_group_label>
    <arm_group_label>OCT only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Aim 1:&#xD;
&#xD;
        . Women who are premenopausal, peri-menopausal and postmenopausal&#xD;
&#xD;
        Aim 2:&#xD;
&#xD;
        . Postmenopausal women with genitourinary syndrome of menopause&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  history of pelvic irradiation&#xD;
&#xD;
          -  Current pregnant or breastfeeding&#xD;
&#xD;
          -  Use of hormone replacement therapy within three months of study enrollment&#xD;
&#xD;
          -  Inability to read and understand english&#xD;
&#xD;
          -  inability to follow research instructions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The study is for women only as it studies vaginal health.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felicia Lane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Afiba Arthur, MD</last_name>
    <phone>9497524700</phone>
    <email>raarthur@hs.uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afiba Arthur</last_name>
      <phone>949-752-4700</phone>
      <email>raarthur@hs.uci.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Felicia Lane</investigator_full_name>
    <investigator_title>Chair, division of FPMRS</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

